Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 5, 2013, Pages 546-554

  Kisiel, J B ^a   Yab, T C ^a   Nazer Hussain, F T ^a   Taylor, W R ^a   Garrity Park, M M ^a   Sandborn, W J ^b   Loftus, E V ^a   Wolff, B G ^a   Smyrk, T C ^a   Itzkowitz, S H ^c   Rubin, D T ^d   Zou, H ^a   Mahoney, D W ^a   Ahlquist, D A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; OSTEOGENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; VIMENTIN;

ADULT; ARTICLE; BMP3 GENE; BRAF GENE; CANCER SCREENING; CLINICAL ARTICLE; COLORECTAL TUMOR; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA DETERMINATION; DNA MARKER; DNA METHYLATION; DYSPLASIA; ENTERITIS; EYA4 GENE; FECES ANALYSIS; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC PROCEDURES; HUMAN; INTESTINE CANCER; INTESTINE DYSPLASIA; INTESTINE MUCOSA; MALE; NDRG4 GENE; ONCOGENE K RAS; PIK3CA GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ALLELE SPECIFIC REAL TIME TARGET AND SIGNAL AMPLIFICATION; SENSITIVITY ANALYSIS; TISSUE SECTION; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS; VIMENTIN GENE;

ADULT; AGED; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FECES; FEMALE; GENETIC MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873412125     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12218     Document Type: Article

References (55)

1. Jess T, Loftus EV Jr, Velayos FS, et al,. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county. Minnesota. Gastroenterology 2006; 130: 1039-46.
2. Howe HL, Wu X, Ries LA, et al,. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 2006; 107: 1711-42.
3. Itzkowitz SH, Harpaz N,. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004; 126: 1634-48.
4. Cairns SR, Scholefield JH, Steele RJ, et al,. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-89.
5. Howdle P, Atkin M, Rutter M, et al,. Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas. London: National Institute for Health and Clinical Excellence (UK), 2011.
6. Nuako KW, Ahlquist DA, Mahoney DW, Schaid DJ, Siems DM, Lindor NM,. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998; 115: 1079-83.
7. Farraye FA, Odze RD, Eaden J, Itzkowitz SH,. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 746-74.
8. Karlen P, Kornfeld D, Brostrom O, Lofberg R, Persson PG, Ekbom A,. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42: 711-4.
9. Loftus EV, Jr,. Does monitoring prevent cancer in inflammatory bowel disease? J Clin Gastroenterol 2003; 36 (Suppl.): S79-83.
10. Collins PD, Mpofu C, Watson AJ, Rhodes JM,. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; 2: CD000279.
11. Subramanian V, Mannath J, Ragunath K, Hawkey CJ,. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 304-12.
12. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH,. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-44.
13. Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT,. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-32.
14. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME,. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-14.
15. Osborn NK, Ahlquist DA,. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128: 192-206.
16. Ahlquist DA, Zou H, Domanico M, et al,. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142: 248-56.
17. Ahlquist DA, Taylor WR, Mahoney DW, et al,. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 272-7 e1.
18. Lidgard GP, Domanico M, Bruinsma JJ, et al,. An optimized multi-marker stool test for colorectal cancer screening: initial clinical appraisal. Gastroenterology 2012; 142 (Suppl. 1): S-770.
19. Taylor HW, Boyle M, Smith SC, Bustin S, Williams NS,. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg 1993; 80: 442-4.
20. Lashner BA, Shapiro BD, Husain A, Goldblum JR,. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 1999; 94: 456-62.
21. Odze RD, Brown CA, Hartmann CJ, Noffsinger AE, Fogt F,. Genetic alterations in chronic ulcerative colitis-associated adenoma-like DALMs are similar to non-colitic sporadic adenomas. Am J Surg Pathol 2000; 24: 1209-16.
22. Bell SM, Kelly SA, Hoyle JA, et al,. c-Ki-ras gene mutations in dysplasia and carcinomas complicating ulcerative colitis. Br J Cancer 1991; 64: 174-8.
23. Holzmann K, Klump B, Borchard F, et al,. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 1998; 76: 1-6.
24. Hirota Y, Tanaka S, Haruma K, et al,. pS2 expression as a possible diagnostic marker of colorectal carcinoma in ulcerative colitis. Oncol Rep 2000; 7: 233-9.
25. Aust DE, Haase M, Dobryden L, et al,. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer 2005; 115: 673-7.
26. Osborn NK, Zou H, Molina JR, et al,. Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clin Gastroenterol Hepatol 2006; 4: 212-8.
27. Issa J-PJ, Ahuja N, Toyota M, Bronner MP, Brentnall TA,. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001; 61: 3573-7.
28. Sato F, Shibata D, Harpaz N, et al,. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 2002; 62: 6820-2.
29. Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ, Bodmer WF,. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut 2001; 48: 367-71.
30. Garrity-Park MM, Loftus EV Jr, Sandborn WJ, Bryant SC, Smyrk TC,. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2010; 105: 1610-9.
31. Watanabe T, Kobunai T, Ikeuchi H, et al,. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol 2011; 38: 201-7.
32. Zou H, Harrington JJ, Shire AM, et al,. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev 2007; 16: 2686-96.
33. Grutzmann R, Molnar B, Pilarsky C, et al,. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 2008; 3: e3759.
34. Garrity-Park MM, Loftus EV Jr, Bryant SC, Sandborn WJ, Smyrk TC,. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2008; 103: 407-15.
35. Fletcher RH, Fletcher SW,. Clinical Epidemiology. 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
36. Gupta RB, Harpaz N, Itzkowitz S, et al,. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-105;.
37. Zou H, Harrington JJ, Klatt KK, Ahlquist DA,. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006; 15: 1115-9.
38. Olson J, Whitney DH, Durkee K, Shuber AP,. DNA stabilization is critical for maximizing performance of fecal DNA-based colorectal cancer tests. Diagn Mol Pathol 2005; 14: 183-91.
39. Kisiel JB, Yab TC, Taylor WR, et al,. Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer 2012; 118: 2623-31.
40. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y,. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8.
41. Ahlquist DA, Sargent DJ, Loprinzi CL, et al,. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149: 441-50.
42. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, (eds.). AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
43. Velayos FS, Liu L, Lewis JD, et al,. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010; 139: 1511-8.
44. Vienne A, Simon T, Cosnes J, et al,. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment Pharmacol Ther 2011; 34: 188-95.
45. Rubenstein JH, Waljee AK, Jeter JM, Velayos FS, Ladabaum U, Higgins PD,. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol 2009; 104: 2222-32.
46. Sato F, Harpaz N, Shibata D, et al,. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 2002; 62: 1148-51.
47. Moriyama T, Matsumoto T, Nakamura S, et al,. Hypermethylation of p14 (ARF) may be predictive of colitic cancer in patients with ulcerative colitis. Dis Colon Rectum 2007; 50: 1384-92.
48. Loh K, Chia JA, Greco S, et al,. Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosom Cancer 2008; 47: 449-60.
49. Melotte V, Lentjes MH, van den Bosch SM, et al,. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 2009; 101: 916-27.
50. Zou H, Osborn NK, Harrington JJ, et al,. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 830-4.
51. Yang WD, Yab TC, Taylor WR, et al,. Aberrant gene methylation in the neoplastic progression of Barrett's esophagus: identification of candidate diagnostic markers. Gastroenterology 2011; 5 (Suppl. 1): S-222.
52. Moinova H, Leidner RS, Ravi L, et al,. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies. Cancer Epidemiol Biomarkers Prev 2012; 21: 594-600.
53. Itzkowitz SH, Jandorf L, Brand R, et al,. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5: 111-7.
54. Itzkowitz S, Brand R, Jandorf L, et al,. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008; 103: 2862-70.
55. Odze RD, Farraye FA, Hecht JL, Hornick JL,. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004; 2: 534-41.